New large-scale pharma plant to be established in Russia by MEP

20 August 2018

One of the largest manufacturing facilities for active pharmaceutical ingredients (APIs) in Russia will soon be built in the Bryansk region of the country, according to the local Ministry of Health, reports The Pharma Letter’s local correspondent.

It is reported that the project will be implemented by the Moscow Endocrine Plant (MEP), a leading Russian producer of drugs which celebrated its 75th anniversary in May this year and became a state enterprise in 1962.

According to recent statements by MEP’s general director Mikhail Fonarev, the value of investments in the project will amount to 6 billion roubles ($89.5 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK